How Serious Is a Tumor on the Heart?

A tumor on the heart ranges from a treatable nuisance to a life-threatening emergency, and the single biggest factor in that range is what kind of tumor it is. Most cardiac tumors found during a person’s lifetime are benign, and the most common benign type can be surgically removed with survival rates that match the general population. Malignant heart tumors, on the other hand, carry some of the worst prognoses in oncology. The distinction between benign and malignant, between a tumor that started in the heart and one that spread there from somewhere else, shapes everything about the diagnosis, treatment, and outlook.

Why Heart Tumors Are So Uncommon

Primary cardiac tumors, meaning growths that originate in the heart itself, are genuinely rare. Autopsy studies put their frequency at roughly 0.3% of the population.¹ Most cardiologists will see only a handful across an entire career. The heart’s constant motion and high blood flow may discourage tumor cell colonization, and heart muscle cells divide so rarely that the mutations behind most cancers have fewer opportunities to take hold.

Tumors that spread to the heart from cancers elsewhere in the body are far more common, estimated at 100 to 1,000 times more frequent than primary cardiac tumors.² These secondary, or metastatic, tumors are a different clinical problem entirely, and they tend to appear in people who already have an advanced cancer diagnosis.

Benign Tumors and the Dominance of the Myxoma

About three-quarters of primary cardiac tumors are benign, and among those, the myxoma is the most frequent by a wide margin. Myxomas are soft, gelatinous growths that typically form in the left atrium, usually attaching by a stalk to the wall separating the two upper chambers of the heart near a small depression called the fossa ovalis.³ They develop from cells in the connective tissue of the heart and are classified as true tumors rather than blood clots or inflammatory masses.⁴

Calling a myxoma “benign” can be misleading if you take that to mean harmless. A myxoma dangling inside the heart on a stalk can block blood flow through the mitral valve, especially when a person changes position, producing sudden shortness of breath or fainting. Some people develop heart failure symptoms that worsen and improve unpredictably, which can lead to misdiagnosis for months. The tumor’s surface can shed fragments into the bloodstream, causing strokes or blockages in arteries supplying other organs. One study of over 300 surgically treated patients found that roughly a quarter experienced an embolic event, including strokes and transient neurological episodes.⁵ Myxomas are considered a significant source of stroke from the heart.⁶

Where the myxoma sits and how it’s shaped also matter. Solid myxomas attached to the atrial septum more often cause heart failure symptoms, while papillary myxomas growing from other sites carry higher rates of embolic complications like stroke.⁷ So even within the “benign” category, the clinical picture varies a lot depending on the tumor’s exact anatomy.

What Happens After Myxoma Surgery

The good news is that surgical removal of a myxoma is well-established and highly effective. In a series spanning 50 years at one center, operative mortality was just 0.5%, and long-term survival at 10, 20, and 30 years was comparable to the general population matched for age.⁸ Another long-term study confirmed that after myxoma resection, patients had survival characteristics not significantly different from an age- and gender-matched population.⁹

Recurrence is the main long-term concern. Myxomas come back in a small but real fraction of patients. One large series reported freedom from recurrence at about 92% at 10 years and 86% at 30 years.⁸ Recurrences tend to occur in younger patients, and the risk decreases substantially after about four years.⁹ For this reason, periodic echocardiography follow-up is standard after surgery to catch any regrowth early.¹⁰

Malignant Primary Tumors Are a Different Story

When a heart tumor is malignant and originated in the heart itself, the prognosis shifts dramatically. These tumors account for roughly a quarter of all primary cardiac tumors, and the most common type is angiosarcoma, a cancer that arises from the cells lining blood vessels within the heart. Angiosarcomas grow aggressively, invade surrounding tissue, and spread early, often to the lungs, liver, and bone.¹¹

The numbers are sobering. A population-level analysis found that median survival for cardiac angiosarcoma was about seven months. Only about a third of patients survived one year, and the five-year survival rate was roughly 10%.¹² These grim numbers stem largely from late detection. Because the heart sits behind the ribcage and early symptoms overlap with more common conditions like heart failure or pericarditis, by the time an angiosarcoma is diagnosed it has usually invaded deeply or spread to distant sites.¹³

For cardiac sarcomas broadly, combining surgery with chemotherapy and radiation roughly doubles median survival compared to surgery alone, extending it to about 19 months from 8 months in one analysis.¹⁴ Even after what surgeons consider a complete resection, recurrence is frequent, and median survival with a primary cardiac sarcoma is around three years when all stages are included.¹⁵ Smaller studies have explored whether adding chemotherapy and radiation after surgery statistically improves things, and the evidence leans positive though it’s difficult to prove definitively given how rare these cancers are.¹⁶

When Cancer Spreads to the Heart From Somewhere Else

Metastatic involvement of the heart is actually the scenario most people with a cardiac tumor face. Cancers that are especially prone to reaching the heart include melanoma and tumors that originate in the chest, like lung cancer and breast cancer, as well as lymphoma.¹⁷ Melanoma has a particular tendency to spread to the heart, though no cancer has an exclusive preference for it.¹⁷

The seriousness of a metastatic heart tumor depends on what it does once there. A small deposit on the outer surface of the heart may never cause symptoms and only shows up on imaging done for other reasons. But tumors that invade the pericardium, the sac surrounding the heart, can cause fluid to accumulate and squeeze the heart, a condition called pericardial effusion. Lung cancer, breast cancer, melanoma, and lymphoma are the most common culprits.¹⁸ When enough fluid builds up, it can compress the heart and prevent it from filling properly, which is a medical emergency. The prognosis in these cases depends more on the underlying cancer than on the cardiac involvement itself, but the heart complications add urgency and can limit treatment options.

How Tumors Cause Symptoms

Heart tumors, whether benign or malignant, produce symptoms through a few main pathways. Their physical mass can obstruct blood flow through chambers or interfere with valve function.¹⁹ A tumor sitting near or on a valve can mimic stenosis or regurgitation, producing the same shortness of breath and fluid retention you’d see with valve disease. If a tumor invades the heart’s electrical system, it can trigger arrhythmias ranging from mild extra beats to dangerous ventricular rhythms, and in extreme cases, sudden cardiac arrest.²⁰ And as mentioned earlier, tumors with friable surfaces shed fragments that embolize, causing strokes and organ damage.

This variety of mechanisms is part of why cardiac tumors are often diagnosed late. A person showing up with heart failure, a new arrhythmia, or a stroke is usually worked up for the common causes of those problems first. Only when imaging is done does the tumor reveal itself.

How Cardiac Tumors Are Found and Characterized

Echocardiography, the standard ultrasound of the heart, is usually the first test to spot a cardiac mass. It’s fast, widely available, and excellent at picking up tumors inside the heart chambers. For myxomas specifically, one study found preoperative echocardiography had a sensitivity of 97%.²¹ A multicentre study found that transesophageal echocardiography, where the ultrasound probe goes down the throat behind the heart, detected 100% of myxomas and was superior to the standard approach for identifying the tumor’s attachment point and any invasion into nearby structures.²²

The harder question is distinguishing benign from malignant. Echocardiography alone struggles here, but scoring systems that factor in features like whether the mass infiltrates surrounding tissue, where it’s located, and whether it’s attached by a stalk or sits broadly on the wall can predict malignancy with over 85% accuracy.²³ Cardiac MRI adds a layer of tissue characterization that echocardiography cannot provide. A meta-analysis of eight studies found that cardiac MRI distinguished benign from malignant tumors with about 93% sensitivity and 94% specificity.²⁴ Features like tumor size, whether it invades neighboring structures, and how it lights up on contrast imaging are the most useful clues.²⁵

Not Every Mass in the Heart Is a Tumor

One important wrinkle in diagnosing cardiac tumors is that many masses found in the heart are not tumors at all. Blood clots, known as thrombi, are far more common than true tumors, and they can look similar on imaging. Vegetations from heart valve infections also mimic tumors. Distinguishing between these requires attention to the mass’s size, location, mobility, and the hemodynamic effects it’s producing, along with the patient’s clinical context.²⁶ A clot in someone with atrial fibrillation or a dilated heart looks very different clinically from a myxoma in an otherwise healthy person, even when the imaging features overlap. This is one reason why cardiac MRI has become increasingly valuable; its ability to characterize tissue type helps clinicians avoid unnecessary surgery for non-tumoral masses.²⁷

Heart Tumors in Children

The landscape of cardiac tumors in children looks very different from adults. The most common pediatric heart tumor is the rhabdomyoma, a benign growth strongly linked to a genetic condition called tuberous sclerosis. In one study of 33 children with rhabdomyomas, 30 had tuberous sclerosis, and the vast majority were detected before the age of one year.²⁸

The remarkable thing about rhabdomyomas is that they usually shrink on their own. Because most of these tumors regress spontaneously, the standard approach is to manage symptoms and wait. Surgery is reserved for life-threatening situations, which in that same series applied to only 2 of 33 patients.²⁸ The speed of regression appears to vary with the specific genetic mutation involved. Children with one type of mutation had a regression rate of about 43%, while those with a different mutation regressed about 25% of the time.²⁹ For parents hearing that their infant has a tumor on the heart, this natural regression pattern is usually reassuring.

Hereditary Syndromes and Cardiac Myxomas

Most myxomas appear sporadically in middle-aged adults with no family history. But a small subset occurs as part of Carney complex, a hereditary condition caused by mutations in a gene called PRKAR1A. This gene helps regulate a signaling pathway involved in cell growth, and when it malfunctions, it predisposes people to myxomas and other tumors throughout the body.³⁰ In a study of 110 cardiac myxomas, two-thirds of those associated with Carney complex had detectable PRKAR1A mutations.³¹

Carney complex matters clinically because affected individuals tend to develop myxomas at younger ages, may develop multiple tumors, and have higher recurrence rates after surgery. If someone under 40 has a myxoma, or if a myxoma recurs after removal, genetic testing for PRKAR1A mutations and screening of family members is worth discussing. The tumor itself is treated the same way, with surgical excision, but the follow-up surveillance needs to be more aggressive and lifelong.

Pushing the Limits of Surgery

For malignant cardiac tumors or benign tumors in difficult-to-reach locations, surgeons sometimes turn to extraordinary techniques. Cardiac autotransplantation involves temporarily removing the patient’s own heart from the body, excising the tumor on a bench where it can be fully visualized, reconstructing the heart, and reimplanting it. A series examining this approach found it feasible for complex left-sided tumors and useful for treating recurrent disease that conventional surgery couldn’t fully reach.³²

Heart transplantation has also been explored for aggressive sarcomas that can’t be removed by any other means. The evidence here is limited and mixed. A small series found that transplantation alone didn’t change long-term outcomes much, but giving chemotherapy before transplantation to shrink the tumor and eliminate microscopic spread, then transplanting the heart for patients who responded, offered a possible path to longer survival.³³ These remain strategies of last resort, used at specialized centers when more conventional options have been exhausted.

The First Successful Cardiac Tumor Surgery

The fact that heart tumors are treatable at all is a relatively recent development. The first successful removal of a cardiac myxoma on cardiopulmonary bypass was performed in 1954 by the Swedish surgeon Clarence Crafoord.³⁴ Before bypass technology made open-heart surgery possible, a cardiac tumor was essentially a death sentence regardless of whether it was benign or malignant. The operation marked not just a milestone for cardiac oncology but for open-heart surgery in general. Less than 70 years later, myxoma removal has become routine enough that operative mortality sits below 1% at experienced centers and patients go home expecting a normal lifespan. The contrast with malignant cardiac tumors, where the five-year survival for angiosarcoma remains around 10%, is a reminder of how much the word “tumor” can mean depending on what’s growing and where.